

April 1, 2023, Full Updates for the Alberta Drug Benefit List (ADBL), Alberta Human Services Drug Benefit Supplement (HSDBS) and Palliative Coverage Drug Benefit Supplement (PCDBS)

Please be advised that the annual April 1, 2023, Full Updates to the *Alberta Drug Benefit List (ADBL)*, *Alberta Human Services Drug Benefit List (HSDBS)* and the *Palliative Coverage Drug Benefit Supplement (PCDBS)* have been posted online at www.ab.bluecross.ca/dbl/publications.php.

Effective April 1, 2023, the following drug products will be removed from the ADBL as the manufacturer did not submit a price to the annual Alberta Price Confirmation process:

As per the Alberta Price Policy, manufacturers with drug products currently listed on the ADBL were invited to re-quote the price of their drug product(s) for continual listing. Please be advised that the following drug products will no longer be listed or eligible for payment under Alberta government-sponsored drug programs effective April 1, 2023, as these manufacturers have chosen not to re-confirm their price.

All drug products scheduled to be removed from the ADBL have been identified as having therapeutic alternatives. *Effective April 1, 2023, the listed products will no longer be a benefit and will not be considered for coverage by Special Authorization. A 30-day transition period will be applied to allow physicians, pharmacists and patients directly affected by these changes sufficient time to transition to another drug therapy as appropriate, and as of May 1, 2023, claims will no longer pay for these products.*

Patients impacted by the removal of these drug products as covered benefits for Alberta government-sponsored drug programs are encouraged to discuss therapeutic alternatives with their health care provider.

DIN/PIN	Product Description
00002493780	Acarbose 50 mg Tablet
00002493799	Acarbose 100 mg Tablet
00000476285	Anusol-HC 10 mg/10 mg Rectal Suppository
00000505773	Anusol-HC Rectal Ointment
00002495899	Calcitriol 0.25 mcg Capsule
00002495902	Calcitriol 0.5 mcg Capsule
00000999455	Consist-Rite Oral Powder
00002495805	Cyclosporine 25 mg Capsule
00002495821	Cyclosporine 50 mg Capsule
00002495813	Cyclosporine 100 mg Capsule
00002041510	Dapsone 100 mg Tablet
00002453797	Entecavir 0.5 mg Tablet

continued next page

continued from previous page

DIN/PIN	Product Description
00002225190	Estrace 0.5 mg Tablet
00002148587	Estrace 1 mg Tablet
00002148595	Estrace 2 mg Tablet
00002085992	K-Lyte 25 mEq Effervescent Tablet

Additionally, effective April 1, 2023, the following drug products will be removed from the ADBL as these drug products have been discontinued by the manufacturer:

The Alberta government-sponsored drug programs previously covered the following drug products; however, notification of discontinuation has been received from the manufacturers. Effective April 1, 2023, the listed products will no longer be a benefit and will not be considered for coverage by Special Authorization. A transition period will apply, and as of May 1, 2023, claims will no longer pay for these products. Patients impacted by the discontinuation of these drug products as covered benefits for Alberta government-sponsored drug programs are encouraged to discuss therapeutic alternatives with their health care provider.

DIN/PIN	Product Description
00002237820	Amerge 1 mg Tablet
00002237821	Amerge 2.5 mg Tablet
00002383055	Bisoprolol 5 mg Tablet
00002383063	Bisoprolol 10 mg Tablet
00000824305	DDAVP 0.1 mg Tablet
00000824143	DDAVP 0.2 mg Tablet
00002242903	Enbrel 25 mg/Vial Injection
00000999404	Ensure Oral Pudding
00001931563	Gastrolyte Oral Powder
00002190885	Glucobay 50 mg Tablet
00002247823	Hepsera 10 mg Tablet
00002239193	Heptovir 100 mg Tablet
00000990101	Inspira Chamber With Mouthpiece
00000990102	Inspira Chamber W/ Medium Inspiramask/Soothemask Device
00000990103	Inspira Chamber W/ Small Inspiramask/Soothemask Device
00002368552	Jamp-Risedronate 35 mg Tablet
00002429233	Jamp-Rizatriptan IR 5 mg Tablet
00002357143	Jamp-Sertraline 25 mg Capsule
00002357178	Jamp-Sertraline 100 mg Capsule
00002420287	Jamp-Tobramycin 40 mg/ml Injection
00002454653	Levetiracetam 250 mg Tablet
00002454661	Levetiracetam 500 mg Tablet
00002454688	Levetiracetam 750 mg Tablet
00002163152	Lidamol 0.05% Topical Emollient Cream

continued next page

PHARMACY BENEFACT

continued from previous page

DIN/PIN	Product Description
00002161923	Lidex 0.05% Topical Cream
00002161974	Lidex 0.05% Topical Gel
00002161966	Lidex 0.05% Topical Ointment
00002162806	Minitran 0.2 mg/hr Transdermal Patch
00002163527	Minitran 0.4 mg/hr Transdermal Patch
00002163535	Minitran 0.6 mg/hr Transdermal Patch
00002230621	Opticrom 2% Ophthalmic Solution
00002231544	pms-Carbamazepine-CR 400 mg Sustained-Release Tablet
00002355442	pms-Celecoxib 100 mg Capsule
00002355450	pms-Celecoxib 200 mg Capsule
00002236466	pms-Domperidone 10 mg Tablet
00002341379	pms-Fentanyl MTX 12 mcg/hr Transdermal Patch
00002341387	pms-Fentanyl MTX 25 mcg/hr Transdermal Patch
00002341395	pms-Fentanyl MTX 50 mcg/hr Transdermal Patch
00002341409	pms-Fentanyl MTX 75 mcg/hr Transdermal Patch
00002341417	pms-Fentanyl MTX 100 mcg/hr Transdermal Patch
00002398389	pms-Galantamine ER 16 mg Extended-Release Capsule
00002398397	pms-Galantamine ER 24 mg Extended-Release Capsule
00002278561	pms-Venlafaxine XR 150 mg Extended-Release Capsule
00002474921	Probuphine 80 mg Subdermal Implant
00002319063	Ran-Gabapentin 300 mg Capsule
00002294249	Ran-Lisinopril 10 mg Tablet
00002294257	Ran-Lisinopril 20 mg Tablet
00002225158	Suprefact Intranasal 1 mg/ml Nasal Solution
00002213419	Ventolin Nebules P.F. 2.5 mg/2.5 ml Inhalation Solution
00002213427	Ventolin Nebules P.F. 5 mg/2.5 ml Inhalation Solution

For a summary of all updates, please refer to the April 1, 2023, Summary of Changes for highlights of products and pricing changes.

Please note that the online *interactive Drug Benefit List (iDBL)* is available at www.ab.bluecross.ca/dbl/idbl_main1.php; this is a near real-time application and as such, contains the most up-to-date information.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

